Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.59 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | JUN | P05412 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2472109 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL620179 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL3011080 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL620443 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL620444 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL2472105 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL4058522 | 0.85 | CHRNB2 (0.74) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL3022184 | 0.85 | CHRNB2 (0.74) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL4058531 | 0.85 | CHRNB2 (0.74) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 | |
| SCHEMBL3022188 | 0.85 | CHRNB2 (0.74) | CHRNB2CHRNA4MEN1KMT2ACHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4240815-B2 | — | — | 2009-03-18 | — | — | JP | claimed |
| US-20080249142-A1 | N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate; compounds can activate nicotinic receptor and can modulate neurotransmitter secretion; neuroprotective agents; side effects reduction; pains; easy to remove impurities; heck coupling reaction; CNS disorders; inflammatory disorders | TARGACEPT, INC. (US) | 2008-10-09 | — | — | US | claimed |
| CN-101068784-A | Hydroxybenzoate salts of metanicotine compounds | TARGACEPT INC (US) | 2007-11-07 | — | — | CN | claimed |
| EP-1814853-A2 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | Targacept, Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| US-20060122238-A1 | Hydroxybenzoate salts of metanicotine compounds | DULL GARY M | 2006-06-08 | — | — | US | claimed |
| WO-2006053039-A2 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| JP-2006511482-A | — | — | 2006-04-06 | — | — | JP | claimed |
| US-6979695-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2005-12-27 | — | — | US | claimed |
| EP-1556352-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2005-07-27 | — | — | EP | claimed |
| EP-1086082-B9 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | TARGACEPT INC (US) | 2005-03-02 | — | — | EP | claimed |
| US-20040214835-A1 | Compounds capable of activating cholinergic receptors | CALDWELL WILLIAM SCOTT (US) | 2004-10-28 | — | — | US | claimed |
| EP-1086082-B1 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | TARGACEPT INC (US) | 2004-08-18 | — | — | EP | claimed |
| WO-2004031151-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2004-04-15 | — | — | WO | claimed |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | TARGACEPT, INC. | 2003-07-03 | — | — | US | claimed |
| JP-2002518373-A | — | — | 2002-06-25 | — | — | JP | claimed |
| US-20020052497-A1 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. | 2002-05-02 | — | — | US | claimed |
| EP-1086082-A1 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2001-03-28 | — | — | EP | claimed |
| WO-1999065876-A1 | ARYL SUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-12-23 | — | — | WO | claimed |
| US-20180092916-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | UNIVERSITY OF SOUTH FLORIDA (US) | 2018-04-05 | — | — | US | disclosed |
| WO-1999043322-A1 | METHOD FOR THE TREATMENT OF PAIN, INCLUDING CHRONIC AND FEMALE SPECIFIC PAIN | WAKE FOREST UNIVERSITY (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052497-A1 | Compounds capable of activating cholinergic receptors | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885MEN1 2465/4885 |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | SLC6A2, CHRNA6, CHRNA10 | CHRNB2 9/4885CHRNA4 7/4885MEN1 1093/4885 |
| US-20180092916-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | CHRNA6, CHRNA7, CHRNA2 | CHRNB2 9/4885CHRNA4 7/4885MEN1 4139/4885 |
| US-20060122238-A1 | Hydroxybenzoate salts of metanicotine compounds | MAOB, SLC6A3, HTT | CHRNB2 564/4885CHRNA4 1861/4885MEN1 171/4885 |
| US-20040214835-A1 | Compounds capable of activating cholinergic receptors | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885MEN1 2465/4885 |
| US-20080249142-A1 | N-methyl-5-(5-isopropoxy-3-pyridinyl)-4-penten-2-amine p-hydroxybenzoate; compounds can activate nicotinic receptor and can modulate neurotransmitter secretion; neuroprotective agents; side effects reduction; pains; easy to remove impurities; heck coupling reaction; CNS disorders; inflammatory disorders | NTRK1, CHRNA10, CHRNB2 | CHRNB2 3/4885CHRNA4 21/4885MEN1 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.